REG - Theracryf PLC - Appointment of Dr Alastair Smith as Chair

TheracryfAnnouncement

19/02/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250219:nRSS7133Xa&default-theme=true

RNS Number : 7133X  Theracryf PLC  19 February 2025

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Experienced life sciences executive, Dr Alastair Smith, appointed Chair

Alderley Park, UK - 19 February 2025: TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on oncology and neuropsychiatry has
appointed Dr Alastair Smith as Non-executive Chair.

Alastair is an experienced life sciences executive, with over 20 years'
experience in public company growth and strategy, having founded and led
Avacta Group plc as CEO from inception until last year. During his tenure,
Avacta evolved into a leading AIM-listed biotech firm with two key divisions:
a clinical-stage oncology drug company advancing its proprietary pre|CISION
tumor-targeting platform and a diagnostics business pursuing an M&A-driven
growth strategy in Europe, focused on serving healthcare professionals.

Alastair also brings valuable R&D and academic leadership, having also
spent over 12 years as Professor of Molecular Biophysics at the University of
Leeds. Alastair is also Non-executive Director of N4 Pharma plc and
Non-executive Chairman of SPARTA Biodiscovery Ltd.

Alastair is stepping into the role of Chair following the passing of former
Chair Dr Sue Foden in November last year. The appointment is effective
immediately. Alastair's directorship fee for at least the next 12 months will
be paid to him in Ordinary Shares.

Dr Huw Jones, CEO of TheraCryf, commented:

"Attracting a Chair of Alastair's calibre and experience is a real endorsement
of the potential of TheraCryf's product portfolio and our approach. We have
been struck by the high quality of our interactions so far and wish him a very
warm welcome to the team. I look forward to working closely with Alastair."

Dr Alastair Smith, incoming Non-executive Chair of TheraCryf, added:

"TheraCryf's product portfolio includes assets addressing areas of high unmet
need and, in particular, the Orexin-1 antagonist candidate has class leading
characteristics and potential to treat patients with addictive disorders such
as alcohol and opioid abuse, and binge eating disorder. This is a key time to
be joining the business as it seeks to complete the final steps, over the next
twelve months or so, to transition the Orexin-1 programme to clinical
readiness - a huge value inflection point for the company.

"I look forward very much to supporting the team to deliver on the
opportunities that clearly exist within the company and to communicate these
opportunities effectively to the market so that progress is reflected by
growth in shareholder value."

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies in relation to Dr David Alastair
Maclaughlin Smith, aged 58:

 

 Current Directorships/Partnerships          Past Directorships/Partnerships (within 5 years)
 N4 Pharma plc                               Avacta Group plc

 Sparta BioDiscovery Limited                 Nextmune Laboratories Ltd (formerly Avacta Animal Health Ltd)

                                             Avacta Animal Health Inc.

                                             Avacta Analytical Limited

                                             Affimer Limited

                                             Avacta Ltd

                                             Avacta Life Sciences Limited

                                             Avacta Life Sciences Inc.

                                             Avacta Group Trustee Limited

                                             Avacta Finance (Jersey) Limited

                                             AffyXell Therapeutics

                                             Crossco (1127) Limited

                                             Launch Diagnostics Holdings Limited

                                             Launch Diagnostics Ltd

                                             Coris BioConcept SrL

                                             Coris Holdings SrL

 

-Ends-

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Vigo Consulting                                             +44 (0)20 7390 0231
 Rozi Morris
theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFEIFVIALIE